Enzalutamide Bests Older NSAAs in mHSPC
- PMID: 31164340
- DOI: 10.1158/2159-8290.CD-NB2019-066
Enzalutamide Bests Older NSAAs in mHSPC
Abstract
According to results from ENZAMET, a global phase III trial, adding enzalutamide to standard treatment for men with metastatic hormone-sensitive prostate cancer is superior in prolonging survival compared with older nonsteroidal antiandrogen drugs.
©2019 American Association for Cancer Research.
Comment on
-
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.N Engl J Med. 2019 Jul 11;381(2):121-131. doi: 10.1056/NEJMoa1903835. Epub 2019 Jun 2. N Engl J Med. 2019. PMID: 31157964 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical